Hikma Pharmaceuticals Plc (HIK) Given Average Recommendation of “Hold” by Brokerages

Shares of Hikma Pharmaceuticals Plc (LON:HIK) have been assigned a consensus recommendation of “Hold” from the ten analysts that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is GBX 1,190 ($16.44).

A number of research firms recently weighed in on HIK. Peel Hunt reaffirmed a “hold” rating and set a GBX 1,390 ($19.20) price objective on shares of Hikma Pharmaceuticals in a research report on Thursday, November 9th. lowered their price objective on shares of Hikma Pharmaceuticals from GBX 1,060 ($14.64) to GBX 865 ($11.95) and set a “reduce” rating for the company in a research report on Friday, November 10th. JPMorgan Chase & Co. lowered their price objective on shares of Hikma Pharmaceuticals from GBX 1,250 ($17.27) to GBX 1,000 ($13.82) and set a “neutral” rating for the company in a research report on Friday, November 10th. Jefferies Group reaffirmed an “underperform” rating and set a GBX 895 ($12.37) price objective on shares of Hikma Pharmaceuticals in a research report on Wednesday, January 17th. Finally, Stifel Nicolaus lowered their price objective on shares of Hikma Pharmaceuticals from GBX 1,320 ($18.24) to GBX 1,000 ($13.82) and set a “hold” rating for the company in a research report on Thursday, November 9th.

Hikma Pharmaceuticals (LON:HIK) opened at GBX 870 ($12.02) on Tuesday. The firm has a market cap of $2,090.00 and a P/E ratio of 1,740.00. Hikma Pharmaceuticals has a 1 year low of GBX 840.60 ($11.61) and a 1 year high of GBX 2,346 ($32.41).

TRADEMARK VIOLATION WARNING: “Hikma Pharmaceuticals Plc (HIK) Given Average Recommendation of “Hold” by Brokerages” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/02/13/hikma-pharmaceuticals-plc-hik-given-average-recommendation-of-hold-by-brokerages.html.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply